Alterity Therapeutics Limited (ATHE)Healthcare | Biotechnology | Melbourne, Australia | NasdaqCM
4.51 USD
-0.05
(-1.096%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.55 +0.04 (0.887%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 6:05 a.m. EDT
The immediate outlook is cautiously constructive, driven by a sharp technical rebound where the stock has recovered significantly from its multi-year lows, trading well above its 200-day moving average. However, this momentum is fragile; the statistical forecasting model offers only a weak lean toward upside with low confidence, suggesting the recent price action may be noise rather than a confirmed trend. The fundamental reality remains stark: the company is burning cash with negative operating margins and no revenue growth history, relying entirely on future clinical trial results for survival. Consequently, while the chart looks like a potential bounce, the underlying business quality does not support a high-conviction long-term hold. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.064339 |
| MSTL | 0.066368 |
| AutoTheta | 0.069042 |
| AutoETS | 0.070031 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 0.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.071 |
| Excess Kurtosis | -0.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.181 |
| Revenue per Share | 22.8 |
| Market Cap | 81,746,888 |
| Forward P/E | -4.56 |
| Beta | -0.04 |
| Profit Margins | -219.85% |
| Website | https://alteritytherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.116279066 |
| Address1 | 500 Collins Street |
| Address2 | Level 15 |
| All Time High | 797.4 |
| All Time Low | 1.0 |
| Ask | 4.56 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 24,130 |
| Average Daily Volume3 Month | 44,530 |
| Average Volume | 44,530 |
| Average Volume10Days | 24,130 |
| Beta | -0.035 |
| Bid | 3.45 |
| Bid Size | 1 |
| Book Value | 107.28115 |
| City | Melbourne |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Australia |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.51 |
| Current Ratio | 21.978 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.83 |
| Day Low | 4.46 |
| Debt To Equity | 0.181 |
| Display Name | Alterity Therapeutics |
| Earnings Timestamp End | 1,754,654,400 |
| Earnings Timestamp Start | 1,754,305,140 |
| Ebitda | -17,550,620 |
| Ebitda Margins | -2.6445901 |
| Enterprise To Ebitda | 2.704 |
| Enterprise To Revenue | -7.15 |
| Enterprise Value | -47,449,036 |
| Eps Current Year | -0.891 |
| Eps Forward | -0.98933 |
| Eps Trailing Twelve Months | -0.58 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.8516 |
| Fifty Day Average Change | -0.34159994 |
| Fifty Day Average Change Percent | -0.070409745 |
| Fifty Two Week Change Percent | -11.627907 |
| Fifty Two Week High | 5.89 |
| Fifty Two Week High Change | -1.3799996 |
| Fifty Two Week High Change Percent | -0.23429535 |
| Fifty Two Week Low | 2.66 |
| Fifty Two Week Low Change | 1.8500001 |
| Fifty Two Week Low Change Percent | 0.69548875 |
| Fifty Two Week Range | 2.66 - 5.89 |
| Financial Currency | AUD |
| First Trade Date Milliseconds | 1,064,842,200,000 |
| Float Shares | 288,035 |
| Forward Eps | -0.98933 |
| Forward P E | -4.558641 |
| Free Cashflow | -10,609,269 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 9 |
| Fullday Change | -0.0499997 |
| Fullday Change Percent | -1.09649 |
| Fullday Price | 4.55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.97546995 |
| Gross Profits | 6,473,641 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.02167 |
| Implied Shares Outstanding | 18,125,694 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,673,222,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia. |
| Long Name | Alterity Therapeutics Limited |
| Market | us_market |
| Market Cap | 81,746,888 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_2383747 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -14,590,342 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 79,656,101 |
| Number Of Analyst Opinions | 4 |
| Open | 4.51 |
| Operating Cashflow | -13,712,459 |
| Operating Margins | -3.72591 |
| Payout Ratio | 0.0 |
| Phone | 61 3 9349 4906 |
| Post Market Change | 0.03999996 |
| Post Market Change Percent | 0.88691705 |
| Post Market Price | 4.55 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 4.56 |
| Price Eps Current Year | -5.061729 |
| Price Hint | 4 |
| Price To Book | 0.042039074 |
| Price To Sales Trailing12 Months | 12.317918 |
| Profit Margins | -2.19853 |
| Quick Ratio | 21.676 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.049999714 |
| Regular Market Change Percent | -1.096485 |
| Regular Market Day High | 4.83 |
| Regular Market Day Low | 4.46 |
| Regular Market Day Range | 4.46 - 4.83 |
| Regular Market Open | 4.51 |
| Regular Market Previous Close | 4.56 |
| Regular Market Price | 4.51 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 11,648 |
| Return On Assets | -0.32543 |
| Return On Equity | -0.47025 |
| Revenue Growth | 0.746 |
| Revenue Per Share | 22.8 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 18,125,694 |
| Shares Percent Shares Out | 0.0014 |
| Shares Short | 24,763 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 38,037 |
| Short Name | Alterity Therapeutics Limited |
| Short Percent Of Float | 0.0014 |
| Short Ratio | 2.33 |
| Source Interval | 15 |
| State | VIC |
| Symbol | ATHE |
| Target High Price | 16.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 13.25 |
| Target Median Price | 13.5 |
| Total Cash | 49,200,548 |
| Total Cash Per Share | 135.72 |
| Total Debt | 98,449 |
| Total Revenue | 6,636,421 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.9792 |
| Two Hundred Day Average Change | 0.53080034 |
| Two Hundred Day Average Change Percent | 0.13339373 |
| Type Disp | Equity |
| Volume | 11,648 |
| Website | https://alteritytherapeutics.com |
| Zip | 3,000 |